218 related articles for article (PubMed ID: 16863427)
1. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.
Xia CQ; Yang JJ; Gan LS
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):595-611. PubMed ID: 16863427
[TBL] [Abstract][Full Text] [Related]
2. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
3. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
5. BCRP/ABCG2 in the placenta: expression, function and regulation.
Mao Q
Pharm Res; 2008 Jun; 25(6):1244-55. PubMed ID: 18202831
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Lepper ER; Nooter K; Verweij J; Acharya MR; Figg WD; Sparreboom A
Pharmacogenomics; 2005 Mar; 6(2):115-38. PubMed ID: 15882131
[TBL] [Abstract][Full Text] [Related]
7. Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
Dallas S; Salphati L; Gomez-Zepeda D; Wanek T; Chen L; Chu X; Kunta J; Mezler M; Menet MC; Chasseigneaux S; Declèves X; Langer O; Pierre E; DiLoreto K; Hoft C; Laplanche L; Pang J; Pereira T; Andonian C; Simic D; Rode A; Yabut J; Zhang X; Scheer N
Mol Pharmacol; 2016 May; 89(5):492-504. PubMed ID: 26893303
[TBL] [Abstract][Full Text] [Related]
8. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Natarajan K; Xie Y; Baer MR; Ross DD
Biochem Pharmacol; 2012 Apr; 83(8):1084-103. PubMed ID: 22248732
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T; Ross DD
Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
[TBL] [Abstract][Full Text] [Related]
10. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2).
Ieiri I
Drug Metab Pharmacokinet; 2012; 27(1):85-105. PubMed ID: 22123128
[TBL] [Abstract][Full Text] [Related]
11. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
13. ABCG2 -- a transporter for all seasons.
Sarkadi B; Ozvegy-Laczka C; Német K; Váradi A
FEBS Lett; 2004 Jun; 567(1):116-20. PubMed ID: 15165903
[TBL] [Abstract][Full Text] [Related]
14. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.
Garimella TS; Ross DD; Eiseman JL; Mondick JT; Joseph E; Nakanishi T; Bates SE; Bauer KS
Cancer Chemother Pharmacol; 2005 Feb; 55(2):101-9. PubMed ID: 15580504
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer resistance protein (BCRP/ABCG2).
Staud F; Pavek P
Int J Biochem Cell Biol; 2005 Apr; 37(4):720-5. PubMed ID: 15694832
[TBL] [Abstract][Full Text] [Related]
16. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
17. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
18. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer resistance protein (BCRP) in acute leukemia.
Plasschaert SL; Van Der Kolk DM; De Bont ES; Vellenga E; Kamps WA; De Vries EG
Leuk Lymphoma; 2004 Apr; 45(4):649-54. PubMed ID: 15160935
[TBL] [Abstract][Full Text] [Related]
20. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.
Haimeur A; Conseil G; Deeley RG; Cole SP
Curr Drug Metab; 2004 Feb; 5(1):21-53. PubMed ID: 14965249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]